Loading...

Adamas Pharmaceuticals

Nasdaq:ADMS
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ADMS
Nasdaq
$137M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Adamas Pharmaceuticals has significant price volatility in the past 3 months.
ADMS Share Price and Events
7 Day Returns
-12.9%
NasdaqGM:ADMS
-0.3%
US Biotechs
-2.1%
US Market
1 Year Returns
-83%
NasdaqGM:ADMS
-5%
US Biotechs
1.3%
US Market
ADMS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Adamas Pharmaceuticals (ADMS) -12.9% -20.2% -55.1% -83% -69.5% -72%
US Biotechs -0.3% -2.5% -5.2% -5% 4.2% 10.1%
US Market -2.1% -4.2% 0% 1.3% 33.5% 38%
1 Year Return vs Industry and Market
  • ADMS underperformed the Biotechs industry which returned -5% over the past year.
  • ADMS underperformed the Market in United States of America which returned 1.3% over the past year.
Price Volatility
ADMS
Industry
5yr Volatility vs Market
Related Companies

ADMS Value

 Is Adamas Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Adamas Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Adamas Pharmaceuticals.

NasdaqGM:ADMS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 11 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 14.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:ADMS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.38
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.379 (1 + (1- 21%) (95.05%))
1.948
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.95
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.948 * 5.96%)
14.34%

Discounted Cash Flow Calculation for NasdaqGM:ADMS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Adamas Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:ADMS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 14.34%)
2019 -91.60 Analyst x1 -80.11
2020 -73.20 Analyst x1 -55.99
2021 -32.10 Analyst x1 -21.47
2022 4.60 Analyst x1 2.69
2023 45.20 Analyst x1 23.13
2024 77.57 Est @ 71.62% 34.71
2025 117.09 Est @ 50.95% 45.83
2026 159.81 Est @ 36.48% 54.71
2027 201.93 Est @ 26.36% 60.46
2028 240.84 Est @ 19.27% 63.06
Present value of next 10 years cash flows $127.01
NasdaqGM:ADMS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $240.84 × (1 + 2.73%) ÷ (14.34% – 2.73%)
$2,131.17
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,131.17 ÷ (1 + 14.34%)10
$558.02
NasdaqGM:ADMS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $127.01 + $558.02
$685.04
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $685.04 / 27.53
$24.88
NasdaqGM:ADMS Discount to Share Price
Calculation Result
Value per share (USD) From above. $24.88
Current discount Discount to share price of $4.99
= -1 x ($4.99 - $24.88) / $24.88
79.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Adamas Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $4.99 vs Future cash flow value of $24.88
Current Discount Checks
For Adamas Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Adamas Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Adamas Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Adamas Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Adamas Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ADMS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-4.61
NasdaqGM:ADMS Share Price ** NasdaqGM (2019-05-24) in USD $4.99
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 17.95x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Adamas Pharmaceuticals.

NasdaqGM:ADMS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ADMS Share Price ÷ EPS (both in USD)

= 4.99 ÷ -4.61

-1.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Adamas Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Adamas Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Adamas Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:ADMS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts
49.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.19x
United States of America Market PEG Ratio Median Figure of 2,120 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Adamas Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Adamas Pharmaceuticals's assets?
Raw Data
NasdaqGM:ADMS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.32
NasdaqGM:ADMS Share Price * NasdaqGM (2019-05-24) in USD $4.99
United States of America Biotechs Industry PB Ratio Median Figure of 418 Publicly-Listed Biotechs Companies 3.19x
United States of America Market PB Ratio Median Figure of 5,207 Publicly-Listed Companies 1.8x
NasdaqGM:ADMS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ADMS Share Price ÷ Book Value per Share (both in USD)

= 4.99 ÷ 2.32

2.15x

* Primary Listing of Adamas Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Adamas Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Adamas Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Adamas Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ADMS Future Performance

 How is Adamas Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
49.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Adamas Pharmaceuticals expected to grow at an attractive rate?
  • Adamas Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Adamas Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Adamas Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ADMS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ADMS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts 49.8%
NasdaqGM:ADMS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts 38.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.4%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ADMS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ADMS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 283 60 30 6
2022-12-31 195 24 -14 6
2021-12-31 139 -24 -45 8
2020-12-31 102 -46 -74 11
2019-12-31 56 -69 -109 9
NasdaqGM:ADMS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 43 -100 -126
2018-12-31 34 -104 -131
2018-09-30 21 -105 -131
2018-06-30 11 -98 -122
2018-03-31 3 -78 -108
2017-12-31 1 -67 -89
2017-09-30 0 -52 -75
2017-06-30 0 -50 -66
2017-03-31 0 -50 -62
2016-12-31 1 -48 -60
2016-09-30 1 -51 -56
2016-06-30 2 -48 -56

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Adamas Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Adamas Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ADMS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below

All data from Adamas Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ADMS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.95 1.89 0.00 2.00
2022-12-31 -0.46 -0.35 -0.56 2.00
2021-12-31 -1.50 -0.33 -2.25 4.00
2020-12-31 -2.65 -1.50 -3.97 8.00
2019-12-31 -3.88 -3.46 -4.29 7.00
NasdaqGM:ADMS Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -4.61
2018-12-31 -4.87
2018-09-30 -5.09
2018-06-30 -4.94
2018-03-31 -4.62
2017-12-31 -3.97
2017-09-30 -3.37
2017-06-30 -2.99
2017-03-31 -2.84
2016-12-31 -2.77
2016-09-30 -2.68
2016-06-30 -2.82

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Adamas Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Adamas Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Adamas Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ADMS Past Performance

  How has Adamas Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Adamas Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Adamas Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Adamas Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Adamas Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Adamas Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Adamas Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ADMS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 43.16 -125.69 110.46 42.33
2018-12-31 34.05 -131.00 109.14 39.30
2018-09-30 21.30 -131.47 104.58 35.15
2018-06-30 10.69 -121.68 93.15 29.90
2018-03-31 3.12 -108.43 78.56 27.27
2017-12-31 0.57 -89.49 61.35 27.17
2017-09-30 0.04 -75.09 46.61 27.77
2017-06-30 0.18 -66.13 39.09 28.75
2017-03-31 0.40 -62.26 35.23 30.80
2016-12-31 0.57 -60.06 30.33 31.23
2016-09-30 1.06 -55.79 31.33 33.88
2016-06-30 1.69 -56.25 28.59 36.40
2016-03-31 1.87 -53.43 25.18 35.88
2015-12-31 1.92 -51.80 23.46 35.90
2015-09-30 31.69 -32.20 21.32 34.72
2015-06-30 31.14 -26.90 19.87 30.17
2015-03-31 55.90 5.30 17.28 26.64
2014-12-31 55.85 8.97 15.47 21.86
2014-09-30 65.66 20.49 13.34 15.72
2014-06-30 65.60 27.51 10.56 11.69
2014-03-31 40.69 6.89 8.66 8.09
2013-12-31 71.10 33.07 6.67 7.41
2013-09-30 67.34 34.62 8.46 7.76
2012-12-31 37.47 11.44 8.33 9.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Adamas Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Adamas Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Adamas Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Adamas Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Adamas Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ADMS Health

 How is Adamas Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Adamas Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Adamas Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Adamas Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Adamas Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Adamas Pharmaceuticals Company Filings, last reported 1 month ago.

NasdaqGM:ADMS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 63.92 130.59 190.64
2018-12-31 89.89 119.12 210.87
2018-09-30 114.40 115.35 211.47
2018-06-30 142.56 111.28 202.98
2018-03-31 169.60 107.11 198.53
2017-12-31 66.13 102.65 173.44
2017-09-30 85.88 35.41 123.73
2017-06-30 103.90 33.77 128.34
2017-03-31 119.75 0.00 112.07
2016-12-31 132.18 0.00 113.65
2016-09-30 144.07 0.00 102.19
2016-06-30 155.16 0.00 156.13
2016-03-31 167.10 0.00 163.28
2015-12-31 116.19 0.00 106.80
2015-09-30 123.99 0.00 103.45
2015-06-30 135.12 0.00 124.47
2015-03-31 137.55 0.00 114.49
2014-12-31 147.07 0.00 122.36
2014-09-30 132.75 0.00 137.53
2014-06-30 140.19 0.00 144.61
2014-03-31 78.37 0.00 79.80
2013-12-31 81.99 0.00 85.61
2013-09-30 47.33 0.00 49.05
2012-12-31 25.82 4.00 62.96
  • Adamas Pharmaceuticals's level of debt (204.3%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 204.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Adamas Pharmaceuticals has sufficient cash runway for 1.9 years based on current free cash flow.
  • Adamas Pharmaceuticals has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 32.5% each year.
X
Financial health checks
We assess Adamas Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Adamas Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ADMS Dividends

 What is Adamas Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Adamas Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Adamas Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Adamas Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Adamas Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ADMS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ADMS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Adamas Pharmaceuticals has not reported any payouts.
  • Unable to verify if Adamas Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Adamas Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Adamas Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Adamas Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Adamas Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Adamas Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Adamas Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ADMS Management

 What is the CEO of Adamas Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gregory Went
COMPENSATION $3,359,123
AGE 54
TENURE AS CEO 19.3 years
CEO Bio

Dr. Gregory T. Went, Ph.D. is a Co-founder and Chairman of NeuroMolecular. Dr. Went co-founded Tethys Bioscience Inc. in 2002 and served as its Chairman of the Board. Dr. Went co-founded Adamas Pharmaceuticals, Inc. and has been its Chairman and Chief Executive Officer since 2000. He actively advised Tethys Bioscience Inc. in new technologies and financing. He served as a Chief Operating Officer of DNA Sciences Inc. since January 2000. He spent a year at DNA Sciences where he joined in 2000 and managed the day-to-day internal operations of DNA Sciences, including the Gene Trust project. Prior to joining, he co founded in 1992 and served as an Executive Vice President of CuraGen Corporation (Nasdaq: CRGN), where he helped build a company of five scientists into one of more than 300 employees. While at CuraGen, Dr. Went contributed to technology and process development. He also produced corporate alliances with Roche, Genentech, Inc., Biogen, Glaxo Wellcome, Inc., and Pioneer Hy-Bred International, Inc. Later, he spearheaded both the business development, private and public financing efforts. He left CuraGen Corporation in 1999. He has been a Director of DNA Sciences Inc. since January 2000. He served as a Member of the Board of Directors of CuraGen Corporation. He also serves as an advisor and board member at Abgenix, Parallele and Nugen. He is a Member of Scientific Advisory Board of Presidio Partners. Dr. Went has published in the fields of spectroscopy and biological profiling and is an inventor on over 20 issued and pending patents. He received a B.S. in Chemical Engineering and Information Systems from Carnegie Mellon University; as Ph.D. in Chemical Engineering from UC Berkeley; and a Post-doc’d at Cornel University.

CEO Compensation
  • Gregory's compensation has increased whilst company is loss making.
  • Gregory's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Adamas Pharmaceuticals management team in years:

2.5
Average Tenure
49
Average Age
  • The tenure for the Adamas Pharmaceuticals management team is about average.
Management Team

Gregory Went

TITLE
Co-Founder
COMPENSATION
$3M
AGE
54
TENURE
19.3 yrs

Alf Merriweather

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
64
TENURE
1.9 yrs

Rajiv Patni

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
49
TENURE
3.9 yrs

Christopher Prentiss

TITLE
Chief Accounting Officer
AGE
43
TENURE
1.7 yrs

Jennifer Rhodes

TITLE
Chief Business Officer
COMPENSATION
$1M
AGE
48
TENURE
3.1 yrs

Sarah Mathieson

TITLE
Head of Corporate Communications & Engagement
TENURE
0.3 yrs

Dean Hart

TITLE
Senior Vice President of Sales

Melissa Masterson

TITLE
Senior Vice President of Commercial Operations & Market Access
Board of Directors Tenure

Average tenure and age of the Adamas Pharmaceuticals board of directors in years:

14.8
Average Tenure
64
Average Age
  • The average tenure for the Adamas Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Gregory Went

TITLE
Co-Founder
COMPENSATION
$3M
AGE
54
TENURE
19.3 yrs

Bill Ericson

TITLE
Independent Director
COMPENSATION
$223K
AGE
59
TENURE
14.3 yrs

David Mahoney

TITLE
Lead Independent Director
COMPENSATION
$241K
AGE
64

Martha Demski

TITLE
Independent Director
COMPENSATION
$232K
AGE
65
TENURE
5.2 yrs

Ivan Lieberburg

TITLE
Independent Director
COMPENSATION
$207K
AGE
68
TENURE
15.3 yrs

Arnold Monto

TITLE
Member of Influenza Advisory Board

Alan Perelson

TITLE
Member of Influenza Advisory Board

Jeff Cummings

TITLE
Scientific & Clinical Advisor

Martin Farlow

TITLE
Member of CNS Advisory Board

Matthew Stern

TITLE
Scientific & Clinical Advisor
Who owns this company?
Recent Insider Trading
  • Adamas Pharmaceuticals insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
21. Mar 19 Sell Jennifer Rhodes Individual 20. Mar 19 20. Mar 19 -1,792 $7.99 $-14,318
21. Mar 19 Sell Gregory Went Individual 20. Mar 19 20. Mar 19 -6,319 $7.99 $-50,489
21. Mar 19 Sell Alfred Merriweather Individual 20. Mar 19 20. Mar 19 -857 $7.99 $-6,847
21. Mar 19 Sell Rajiv Patni Individual 20. Mar 19 20. Mar 19 -2,374 $8.00 $-18,992
21. Mar 19 Sell Christopher Prentiss Individual 20. Mar 19 20. Mar 19 -1,185 $8.00 $-9,480
26. Dec 18 Sell Christopher Prentiss Individual 20. Dec 18 20. Dec 18 -228 $7.51 $-1,712
21. Dec 18 Sell Jennifer Rhodes Individual 20. Dec 18 20. Dec 18 -425 $7.52 $-3,196
08. Nov 18 Buy Gregory Went Individual 07. Nov 18 07. Nov 18 3,850 $12.98 $49,956
21. Sep 18 Sell Alfred Merriweather Individual 21. Sep 18 21. Sep 18 -1,665 $19.18 $-31,935
22. Jun 18 Sell Jennifer Rhodes Individual 21. Jun 18 21. Jun 18 -1,002 $25.48 $-25,531
22. Jun 18 Sell Richard King Individual 21. Jun 18 21. Jun 18 -2,501 $25.48 $-63,725
X
Management checks
We assess Adamas Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Adamas Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ADMS News

Simply Wall St News

Introducing Adamas Pharmaceuticals (NASDAQ:ADMS), The Stock That Tanked 82%

View our latest analysis for Adamas Pharmaceuticals Adamas Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Adamas Pharmaceuticals grew its revenue by 1281% over the last year. … We'd recommend taking a very close look at the stock (and any available forecasts), before considering a purchase, because the share price is not correlated with the revenue growth, that's for sure.

Simply Wall St -

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS): What Does Its Beta Value Mean For Your Portfolio?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Did Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Insiders Sell Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So we'll take a look at whether insiders have been buying or selling shares in Adamas Pharmaceuticals, Inc. … In the last twelve months, the biggest single sale by an insider was when Co-Founder Gregory Went sold US$117k worth of shares at a price of US$25.75 per share.

Simply Wall St -

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS): What Does Its Beta Value Mean For Your Portfolio?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Simply Wall St -

Adamas Pharmaceuticals Inc (NASDAQ:ADMS): Are Analysts Optimistic?

With the latest financial year loss of -US$89m and a trailing-twelve month of -US$122m, the US$517m market-cap amplifies its loss by moving further away from its breakeven target? … The most pressing concern for investors is ADMS’s path to profitability – when will it breakeven. … In this article, I will touch on the expectations for ADMS’s growth and when analysts expect the company to become profitable

Simply Wall St -

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Is Trading At A 21.76% Discount

How far off is Adamas Pharmaceuticals Inc (NASDAQ:ADMS) from its intrinsic value? … by taking the expected future cash flows and discounting them to their present value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

When Can We Expect A Profit From Adamas Pharmaceuticals Inc (NASDAQ:ADMS)?

With the latest financial year loss of -US$89.49m and a trailing-twelve month of -US$108.43m, the US$704.78m market-cap amplifies its loss by moving further away from its breakeven target. … I’ve put together a brief outline of industry analyst expectations for ADMS, its year of breakeven and its implied growth rate … Expectation from Biotechs analysts is ADMS is on the verge of breakeven.

Simply Wall St -

Adamas Pharmaceuticals Inc's (NASDAQ:ADMS) Earnings Dropped -49.01%, How Did It Fare Against The Industry?

When Adamas Pharmaceuticals Inc's (NASDAQ:ADMS) announced its latest earnings (31 December 2017), I wanted to understand how these figures stacked up against its past performance. … The two benchmarks I used were Adamas Pharmaceuticals's average earnings over the past couple of years, and its industry performance. … Each year, for the past five years Adamas Pharmaceuticals has seen an annual decline in revenue of -39.25%, on average.

Simply Wall St -

Adamas Pharmaceuticals Inc (NASDAQ:ADMS): Immense Growth Potential?

In December 2017, Adamas Pharmaceuticals Inc (NASDAQ:ADMS) announced its latest earnings update, which showed that losses became smaller relative to the prrior year's level as a result of recent tailwinds Below is a brief commentary on my key takeaways on how market analysts predict Adamas Pharmaceuticals's earnings growth trajectory over the next few years and whether the future looks brighter. … View our latest analysis for Adamas Pharmaceuticals Analysts' outlook for this coming year seems pessimistic, with earnings becoming even more negative, generating -US$156.97M in 2019. … This means, we can anticipate Adamas Pharmaceuticals will grow its earnings by 45.42% every year for the next few years.

Simply Wall St -

Investors In Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Are Paying Above The Intrinsic Value

5-year cash flow estimate 2018 2019 2020 2021 2022 Levered FCF ($, Millions) $-105.60 $-86.90 $-35.00 $68.23 $109.93 Source Analyst x3 Analyst x2 Analyst x1 Analyst x3 Analyst x3 Present Value Discounted @ 11.57% $-94.65 $-69.81 $-25.20 $44.04 $63.59 Present Value of 5-year Cash Flow (PVCF)= $-82 The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. … Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = $110 × (1 + 2.5%) ÷ (11.6% – 2.5%) = $1,238 Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = $1,238 / ( 1 + 11.6%)5 = $716 The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is $634. … NasdaqGM:ADMS Intrinsic Value Feb 20th 18 Important assumptions I'd like to point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows.

Simply Wall St -

ADMS Company Info

Description

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer’s type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Details
Name: Adamas Pharmaceuticals, Inc.
ADMS
Exchange: NasdaqGM
Founded: 2000
$137,390,722
27,533,211
Website: http://www.adamaspharma.com
Address: Adamas Pharmaceuticals, Inc.
1900 Powell Street,
Suite 750,
Emeryville,
California, 94608,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ADMS Common Stock Nasdaq Global Market US USD 10. Apr 2014
DB 136 Common Stock Deutsche Boerse AG DE EUR 10. Apr 2014
Number of employees
Current staff
Staff numbers
154
Adamas Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/25 00:41
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/05/10
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.